[{"orgOrder":0,"company":"Microviable Therapeutics","sponsor":"Inmunomet Intolerancia y Disbiosis SL","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Other Large Molecule","year":"2022","type":"Financing","leadProduct":"MVT-201","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Microviable Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Microviable Therapeutics \/ Inmunomet Intolerancia y Disbiosis SL","highestDevelopmentStatusID":"4","companyTruncated":"Microviable Therapeutics \/ Inmunomet Intolerancia y Disbiosis SL"},{"orgOrder":0,"company":"SOM Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Eravacycline","moa":"30S ribosomal subunit","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"SOM Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SOM Biotech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SOM Biotech \/ Inapplicable"},{"orgOrder":0,"company":"Pulmobiotics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Pulmobiotics Engineered Live Biotherapeutic","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Pulmobiotics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pulmobiotics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Pulmobiotics \/ Inapplicable"},{"orgOrder":0,"company":"Grifols International","sponsor":"Endpoint Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Protein","year":"2022","type":"Collaboration","leadProduct":"Antithrombin III","moa":"Serine protease","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Grifols International","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Grifols International \/ Endpoint Health","highestDevelopmentStatusID":"4","companyTruncated":"Grifols International \/ Endpoint Health"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Pulmobiotics’ engineered live biotherapeutic significantly reduced antibiotic-resistant pseudomonas aeruginosa infections in the lungs of mice, improving survival rates, and dissolved biofilms formed on endotracheal tubes of patients with VAP.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 19, 2023

                          Lead Product(s) : Pulmobiotics Engineered Live Biotherapeutic

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Microviable will use the seed funding to enhance their therapeutic development platform and advance their pipeline to the clinical stage, including lead product, MVT-201, at pre-clinical stage with positive results, and it is an unique biological drug fo...

                          Product Name : MVT-201

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          April 19, 2022

                          Lead Product(s) : MVT-201

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Inmunomet Intolerancia y Disbiosis SL

                          Deal Size : $1.6 million

                          Deal Type : Financing

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : As part of the agreement, Grifols will contribute its industry-leading expertise in plasma-protein therapies and be the exclusive supplier of Antithrombin III (AT-III), a plasma protein that treats patients with blood clotting issues.

                          Product Name : AT-III

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          February 24, 2022

                          Lead Product(s) : Antithrombin III

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Endpoint Health

                          Deal Size : $25.0 million

                          Deal Type : Collaboration

                          blank

                          04

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Pharma Mar has obtained MHRA approval for UK patients to participate in the Phase III NEPTUNO clinical trial, which will determine the efficacy of Aplidin® for the treatment of hospitalized patients with moderate COVID-19 infection.

                          Product Name : Aplidin

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          February 17, 2021

                          Lead Product(s) : Plitidepsin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : In vitro experiments confirmed inhibition of the protease with an IC50 in the low micromolar range. Eravacycline inhibits the infection of SARS-CoV-2 in VeroE6 cells and shows no toxicity when applied alone.

                          Product Name : TP-434

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 19, 2020

                          Lead Product(s) : Eravacycline

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : PharmaMar will contact regulatory authorities to analyze the possibilities of studies on patients infected with Covid-19.

                          Product Name : Aplidin

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          March 13, 2020

                          Lead Product(s) : Plitidepsin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank